Doctors blast Biogen Alzheimer approval as ‘regulatory failure’
Top researchers who advised the U.S. Food and Drug Administration on Biogen Inc.s Alzheimers drug blasted the agency for approving it, calling the decision a “regulatory failure that is “at odds with the evidence.
The New England Journal of Medicine opinion…
